The European Union has long recognized the importance of preventing medicines shortages. This issue has gained renewed urgency in light of recent events, such as the COVID-19 pandemic and ongoing geopolitical tensions, which have exposed significant vulnerabilities within the EU’s pharmaceutical supply chains. In recognition
Artiștii interpreți și executanți beneficiază de protecție legală în calitate de titulari ai drepturilor conexe dreptului de autor. Aceasta categorie de drepturi conferă o protecție similară celei recunoscute autorilor, permițând titularilor să autorizeze ori să interzică utilizarea propriilor interpretări ori execuții. Cu toate acestea, aceste
Ensuring access to innovative medicines for the population is a key objective, recognized at both the European level[1] and at the national level[2], acting as a genuine impetus for national authorities to develop a legal framework that is equally properly aligned with this aim. However,
On 26 January 2024, the European Commission (the „EC”) published a comprehensive report (the „Report”) aimed to outline the recent competition enforcement in the pharmaceutical sector carried out by the EC and the national competition authorities (the „NCAs”) from 2018 to 2022. This Report highlights